Head & Neck Radiotherapy & Osteoradionecrosis Risk

01 — Risk Factors

What raises osteoradionecrosis (ORN) risk

ORN risk reflects radiation dose to the bone, the site irradiated, and the timing of surgery. No single threshold is universally agreed; the figures below are convergence points across reviews, not hard cut-offs.

Dose to site

Radiation dose

Risk rises notably above ~50–60 Gy to the implant site
Reported implant survival ~84% (<50 Gy) vs ~71% (>50 Gy)
High dose compromises bone vascularity & cellularity
Dose–failure relationship is debated; some reviews find no clear cut-off

Anatomic site

Mandible > maxilla

Mandible carries higher ORN risk than maxilla
Posterior mandible most vulnerable (denser, end-artery supply)
Maxilla better vascularized → lower ORN incidence
IMRT planning may spare future implant sites

Timing

Timing vs radiotherapy

Placement before RT avoids irradiated-bone surgery but constrains fields
Post-RT: a delayed interval allows partial tissue recovery
Many advise waiting ≥ 6–12 months after RT where feasible
Lifelong ORN risk persists; it does not fully resolve

02 — Decision Pathway

Interactive risk selector

Estimate the radiation dose delivered to the proposed implant site (from the radiation oncology dose plan), then factor in site and timing. This selector triages risk — it does not replace multidisciplinary review.

Tap the dose band that best matches the planned implant site.

Step 1 — What dose did the implant site receive?

LOW DOSE

< 50 Gy to the site, > 6–12 mo post-RT

Often maxilla or spared field; recovery interval elapsed.

INTERMEDIATE

~50–60 Gy, or recent RT / mandible

Borderline dose, shorter interval, or higher-risk site.

HIGH DOSE

> 60 Gy to the site, esp. mandible

Heavily irradiated bone; markedly elevated ORN risk.

▾

03 — Quick Reference

Factor → risk → action

Treat any high-risk finding as a reason to defer or refer. ORN, once established, is difficult to manage; prevention and case selection dominate.

Factor	Risk level	Action
Site dose < 50 Gy	Lower	Proceed with caution; informed consent on residual lifelong ORN risk.
Site dose ~50–60 Gy	Elevated	Defer if elective; if proceeding, multidisciplinary planning, atraumatic technique.
Site dose > 60 Gy	High	Avoid where alternatives exist; refer to a specialist/cancer center.
Mandible vs maxilla	Mandible higher	Weight risk upward for mandibular sites, esp. posterior.
Recent RT (< 6 mo)	Elevated	Allow a recovery interval before elective placement where feasible.
Hyperbaric oxygen (HBO)	Uncertain	Routine prophylactic HBO not supported by RCTs (HOPON, DAHANCA-21); use case-by-case.

Reference

Sources & clinical disclaimer

For licensed clinicians — educational use only. This algorithm summarizes published, largely observational evidence and is not a substitute for individual clinical judgment, examination, or the standard of care in your jurisdiction. Dose thresholds are debated and ORN risk is patient-specific. Coordinate with the patient's radiation oncologist and surgical team to obtain the actual site dose and to plan management before any procedure in irradiated bone.

Schiegnitz E, Al-Nawas B, et al. Survival of dental implants and occurrence of osteoradionecrosis in irradiated head and neck cancer patients: a systematic review and meta-analysis. Clin Oral Investig. 2021;25(7):4283–4296.
Watson E, et al. Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy: ISOO–MASCC–ASCO Guideline. J Clin Oncol. 2024;42(14):1681–1709.
Shaw RJ, et al. HOPON (Hyperbaric Oxygen for the Prevention of Osteoradionecrosis): A Randomized Controlled Trial of Hyperbaric Oxygen to Prevent Osteoradionecrosis of the Irradiated Mandible After Dentoalveolar Surgery. Int J Radiat Oncol Biol Phys. 2019;104(3):530–539.

Last reviewed: June 2026 · Next review due: June 2027 · Version 1.0